Showing results (821-830 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|September 17, 2023
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 studyNiels W C J van de Donk, Monique C Minnema, Bronno van der Holt, et al.
The Lancet. Oncology|September 11, 2023
Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trialRobert W Mutter, Sharmila Giri, Briant F Fruth, et al.
The Lancet. Oncology|March 14, 2026
Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation studyGil Shamai, Shachar Cohen, Yoav Binenbaum, et al.
The Lancet. Oncology|March 13, 2026
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trialHua Zhong, Jing Wang, Runxiang Yang, et al.
The Lancet. Oncology|March 5, 2026
An international modified Delphi study to prioritise levels of evidence and outcomes to appraise radiotherapy innovation in the ESTRO Value-Based Radiation Oncology frameworkMiet Vandemaele, Michelle Leech, Marianne Aznar, et al.
The Lancet. Oncology|March 5, 2026
Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapyAntonio Angrisani, Youlia Kirova, Azadeh Abravan, et al.
The Lancet. Oncology|April 30, 2026
Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancersZachary J Ward, Fabio Ynoe Moraes, Andrew M Scott, et al.
The Lancet. Oncology|April 30, 2026
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trialSeth A Wander, Maxwell R Lloyd, Jennifer C Keenan, et al.
The Lancet. Oncology|May 14, 2026
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudyAdrian Murray Brunt, Fay H Cafferty, Anna M Kirby, et al.
The Lancet. Oncology|June 10, 2026
Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trialJames P Buteau, Daniel Moon, Michael T Fahey, et al.
Pageof 336